YOUR BUSINESS AUTHORITY

Springfield, MO

Log in Subscribe

Bristol-Myers to buy Celgene in $74B deal

Posted online

Pharmaceutical company Bristol-Myers Squibb agreed to buy cancer drugmaker Celgene in a cash-and-stock deal valued at $74 billion.

“Together with Celgene, we are creating an innovative biopharma leader, with leading franchises and a deep and broad pipeline that will drive sustainable growth and deliver new options for patients across a range of serious diseases,” Bristol-Myers Squibb Chairman and CEO Giovanni Caforio said in a news release.

Celgene shareholders are slated to receive a Bristol-Myers share and $50 in cash for each share held in Celgene.

Read more from CNBC.

Comments

No comments on this story |
Please log in to add your comment
Editors' Pick
Open For Business: 9 Lives Tavern

Shortly after getting married, Amos and Shelby Hale became first-time business owners with the July 10 launch of 9 Lives Tavern in downtown Ozark.

Most Read
Update cookies preferences